OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development
20 Novembre 2024 - 1:00PM
OXB to host a free webinar on
accelerating development of viral vectors through automated
manufacturing and analytical development
Oxford, UK – 20 November
2024: OXB (LSE: OXB), a quality and innovation-led
cell and gene therapy CDMO, today announces it will host a free
60-minute webinar exploring how advanced robotics can be used to
speed up the development of viral vector drug products.
The webinar titled "Accelerating Viral Vector
Manufacturing: The Use of Automation from Early Stage to QC
Release" will be held on Monday 9 December 2024 at 16:00 GMT /
11:00 EST / 17:00 CET.
The webinar will feature presentations by:
-
André Raposo, PhD, Director, Innovation Department at OXB
-
Gareth McCathie, PhD, Group Lead, Innovation Department at OXB
-
Thomas Evans, Principal Scientist, Innovation Department at
OXB
The speakers will showcase OXB's automation
expertise in viral vector manufacturing, highlighting how automated
systems and digital tools are used to optimise production processes
and analytical workflows. The presentation will include case
studies on transfection optimisation and the implementation of
automated analytical methods such as qPCR, ELISA, and cell-based
assays.
The presentations will be followed by a live
Q&A session. To register for the webinar, please click
here.
-Ends-
Enquiries: OXB:Sebastien
Ribault, Chief Business Officer – T: +44 (0) 1865 509 737 / E:
partnering@oxb.comICR Healthcare:T: +44 (0)20 3709
5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide
Salvi
About OXB
OXB (LSE: OXB) is a
quality and innovation-led contract development and manufacturing
organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life-changing therapies to patients
around the world.
One of the original
pioneers in cell and gene therapy, OXB has more than 25 years of
experience in viral vectors; the driving force behind the majority
of cell and gene therapies. OXB collaborates with some of the
world's most innovative pharmaceutical and biotechnology companies,
providing viral vector development and manufacturing expertise in
lentivirus, adeno-associated virus (AAV), adenovirus and other
viral vector types. OXB's world-class capabilities span from
early-stage development to commercialisation. These capabilities
are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
OXB offers a vast
number of unique technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the
TetraVecta™ system), dual plasmid system for AAV production,
suspension and perfusion process using process enhancers and stable
producer and packaging cell lines.
OXB, a FTSE4Good
constituent, is headquartered in Oxford, UK. It has bioprocessing
and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and near Boston, MA, US. Learn more at
www.oxb.com, and follow us on LinkedIn and YouTube.
Grafico Azioni Oxford Biomedica (LSE:OXB)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Oxford Biomedica (LSE:OXB)
Storico
Da Dic 2023 a Dic 2024
